These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

490 related articles for article (PubMed ID: 33289192)

  • 21. Clinical Characteristics and Immune Injury Mechanisms in 71 Patients with COVID-19.
    Wu Y; Huang X; Sun J; Xie T; Lei Y; Muhammad J; Li X; Zeng X; Zhou F; Qin H; Shao L; Zhang Q
    mSphere; 2020 Jul; 5(4):. PubMed ID: 32669467
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Coronavirus disease 2019 (COVID-19): An overview of the immunopathology, serological diagnosis and management.
    Anka AU; Tahir MI; Abubakar SD; Alsabbagh M; Zian Z; Hamedifar H; Sabzevari A; Azizi G
    Scand J Immunol; 2021 Apr; 93(4):e12998. PubMed ID: 33190302
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A double edged-sword - The Complement System during SARS-CoV-2 infection.
    Santiesteban-Lores LE; Amamura TA; da Silva TF; Midon LM; Carneiro MC; Isaac L; Bavia L
    Life Sci; 2021 May; 272():119245. PubMed ID: 33609539
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The triumvirate of NF-κB, inflammation and cytokine storm in COVID-19.
    Attiq A; Yao LJ; Afzal S; Khan MA
    Int Immunopharmacol; 2021 Dec; 101(Pt B):108255. PubMed ID: 34688149
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Involvement of the complement cascade in severe forms of COVID-19].
    Chouaki Benmansour N; Carvelli J; Vivier É
    Med Sci (Paris); 2021 Apr; 37(4):333-341. PubMed ID: 33835019
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Hyperinflammatory Immune Response and COVID-19: A Double Edged Sword.
    Tan LY; Komarasamy TV; Rmt Balasubramaniam V
    Front Immunol; 2021; 12():742941. PubMed ID: 34659238
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Lectin Pathway Mediates Complement Activation by SARS-CoV-2 Proteins.
    Ali YM; Ferrari M; Lynch NJ; Yaseen S; Dudler T; Gragerov S; Demopulos G; Heeney JL; Schwaeble WJ
    Front Immunol; 2021; 12():714511. PubMed ID: 34290717
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effects of β-Blockers on the Sympathetic and Cytokines Storms in Covid-19.
    Al-Kuraishy HM; Al-Gareeb AI; Mostafa-Hedeab G; Kasozi KI; Zirintunda G; Aslam A; Allahyani M; Welburn SC; Batiha GE
    Front Immunol; 2021; 12():749291. PubMed ID: 34867978
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Tocilizumab in SARS-CoV-2 Patients with the Syndrome of Cytokine Storm: A Narrative Review.
    Kulanthaivel S; Kaliberdenko VB; Balasundaram K; Shterenshis MV; Scarpellini E; Abenavoli L
    Rev Recent Clin Trials; 2021; 16(2):138-145. PubMed ID: 32940187
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pro- and Anti-Inflammatory Responses in Severe COVID-19-Induced Acute Respiratory Distress Syndrome-An Observational Pilot Study.
    Notz Q; Schmalzing M; Wedekink F; Schlesinger T; Gernert M; Herrmann J; Sorger L; Weismann D; Schmid B; Sitter M; Schlegel N; Kranke P; Wischhusen J; Meybohm P; Lotz C
    Front Immunol; 2020; 11():581338. PubMed ID: 33123167
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A Cytokine Circus with a Viral Ringleader: SARS-CoV-2-Associated Cytokine Storm Syndromes.
    Cabler SS; French AR; Orvedahl A
    Trends Mol Med; 2020 Dec; 26(12):1078-1085. PubMed ID: 33051104
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Innate Receptor Activation Patterns Involving TLR and NLR Synergisms in COVID-19, ALI/ARDS and Sepsis Cytokine Storms: A Review and Model Making Novel Predictions and Therapeutic Suggestions.
    Root-Bernstein R
    Int J Mol Sci; 2021 Feb; 22(4):. PubMed ID: 33672738
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Status of mannose-binding lectin (MBL) and complement system in COVID-19 patients and therapeutic applications of antiviral plant MBLs.
    Gupta A; Gupta GS
    Mol Cell Biochem; 2021 Aug; 476(8):2917-2942. PubMed ID: 33745077
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Monocyte-driven atypical cytokine storm and aberrant neutrophil activation as key mediators of COVID-19 disease severity.
    Vanderbeke L; Van Mol P; Van Herck Y; De Smet F; Humblet-Baron S; Martinod K; Antoranz A; Arijs I; Boeckx B; Bosisio FM; Casaer M; Dauwe D; De Wever W; Dooms C; Dreesen E; Emmaneel A; Filtjens J; Gouwy M; Gunst J; Hermans G; Jansen S; Lagrou K; Liston A; Lorent N; Meersseman P; Mercier T; Neyts J; Odent J; Panovska D; Penttila PA; Pollet E; Proost P; Qian J; Quintelier K; Raes J; Rex S; Saeys Y; Sprooten J; Tejpar S; Testelmans D; Thevissen K; Van Buyten T; Vandenhaute J; Van Gassen S; Velásquez Pereira LC; Vos R; Weynand B; Wilmer A; Yserbyt J; Garg AD; Matthys P; Wouters C; Lambrechts D; Wauters E; Wauters J
    Nat Commun; 2021 Jul; 12(1):4117. PubMed ID: 34226537
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The effects of novel coronavirus (SARS-CoV-2) infection on cardiovascular diseases and cardiopulmonary injuries.
    Li N; Zhu L; Sun L; Shao G
    Stem Cell Res; 2021 Mar; 51():102168. PubMed ID: 33485182
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Coronavirus infection: An immunologists' perspective.
    De Sanctis JB; García AH; Moreno D; Hajduch M
    Scand J Immunol; 2021 Jun; 93(6):e13043. PubMed ID: 33783027
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Long-acting nanoparticulate DNase-1 for effective suppression of SARS-CoV-2-mediated neutrophil activities and cytokine storm.
    Lee YY; Park HH; Park W; Kim H; Jang JG; Hong KS; Lee JY; Seo HS; Na DH; Kim TH; Choy YB; Ahn JH; Lee W; Park CG
    Biomaterials; 2021 Jan; 267():120389. PubMed ID: 33130319
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Endothelial dysfunction and immunothrombosis as key pathogenic mechanisms in COVID-19.
    Bonaventura A; Vecchié A; Dagna L; Martinod K; Dixon DL; Van Tassell BW; Dentali F; Montecucco F; Massberg S; Levi M; Abbate A
    Nat Rev Immunol; 2021 May; 21(5):319-329. PubMed ID: 33824483
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Immunothrombosis in COVID-19: Implications of Neutrophil Extracellular Traps.
    Bautista-Becerril B; Campi-Caballero R; Sevilla-Fuentes S; Hernández-Regino LM; Hanono A; Flores-Bustamante A; González-Flores J; García-Ávila CA; Aquino-Gálvez A; Castillejos-López M; Juárez-Cisneros A; Camarena A
    Biomolecules; 2021 May; 11(5):. PubMed ID: 34066385
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Immune reactivity during COVID-19: Implications for treatment.
    Napoli C; Benincasa G; Criscuolo C; Faenza M; Liberato C; Rusciano M
    Immunol Lett; 2021 Mar; 231():28-34. PubMed ID: 33421440
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 25.